- Home
- EDIT vs IGI Comparison
EDIT vs IGI Comparison
Compare EDIT & IGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- IGI
- Stock Information
- Founded
- EDIT 2013
- IGI 2009
- Country
- EDIT United States
- IGI United States
- Employees
- EDIT N/A
- IGI N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- IGI Investment Managers
- Sector
- EDIT Health Care
- IGI Finance
- Exchange
- EDIT Nasdaq
- IGI Nasdaq
- Market Cap
- EDIT 176.7M
- IGI 180.3M
- IPO Year
- EDIT 2016
- IGI N/A
- Fundamental
- Price
- EDIT $1.32
- IGI $16.64
- Analyst Decision
- EDIT Buy
- IGI
- Analyst Count
- EDIT 14
- IGI 0
- Target Price
- EDIT $8.08
- IGI N/A
- AVG Volume (30 Days)
- EDIT 3.3M
- IGI 33.9K
- Earning Date
- EDIT 11-04-2024
- IGI 01-01-0001
- Dividend Yield
- EDIT N/A
- IGI 4.79%
- EPS Growth
- EDIT N/A
- IGI N/A
- EPS
- EDIT N/A
- IGI N/A
- Revenue
- EDIT $61,759,000.00
- IGI N/A
- Revenue This Year
- EDIT N/A
- IGI N/A
- Revenue Next Year
- EDIT N/A
- IGI N/A
- P/E Ratio
- EDIT N/A
- IGI N/A
- Revenue Growth
- EDIT 150.95
- IGI N/A
- 52 Week Low
- EDIT $1.28
- IGI $15.13
- 52 Week High
- EDIT $11.58
- IGI $17.79
- Technical
- Relative Strength Index (RSI)
- EDIT 24.88
- IGI 31.16
- Support Level
- EDIT $1.28
- IGI $16.77
- Resistance Level
- EDIT $2.37
- IGI $16.94
- Average True Range (ATR)
- EDIT 0.18
- IGI 0.12
- MACD
- EDIT -0.04
- IGI -0.02
- Stochastic Oscillator
- EDIT 6.45
- IGI 0.00
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.